December 28, 2011Open Access

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

The use of bevacizumab during and up to 10 months after carboplatin and paclitaxel chemotherapy prolongs the median progression-free survival by about 4 months in patients with advanced epithelial ovarian cancer. (Funded by the National Cancer Institute and Genentech; ClinicalTrials.gov number, NCT00262847.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Robert A. Burger

Mark F. Brady

Michael A. Bookman

Journals

New England Journal of Medicine

Actions

Institutions

Harvard University

University of Chicago

Massachusetts General Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study